Research programme: gene therapy - BEAT BioTherapeutics

Drug Profile

Research programme: gene therapy - BEAT BioTherapeutics

Alternative Names: BB R12

Latest Information Update: 08 Jun 2015

Price : $50

At a glance

  • Originator University of Washington
  • Developer BEAT BioTherapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 04 Jun 2015 Pharmacodynamics data from a preclinical trial in Heart failure released by BEAT BioTherapeutics
  • 16 Apr 2013 Preclinical trials in Heart failure in USA (Parenteral)
  • 16 Apr 2013 BEAT BioTherapeutics holds an exclusive worldwide license to BB R12 from the University of Washington
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top